<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822521</url>
  </required_header>
  <id_info>
    <org_study_id>2014P002312</org_study_id>
    <nct_id>NCT02822521</nct_id>
  </id_info>
  <brief_title>A Novel Mobile App &amp; Population Management System to Manage Rheumatoid Arthritis Flares</brief_title>
  <official_title>A Novel Mobile App &amp; Population Management System to Manage Rheumatoid Arthritis Flares</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this proposal is to implement a smart phone application (app) +
      population management system to monitor rheumatoid arthritis (RA) disease activity between
      scheduled physician office visits. The population management system includes: 1) a web-based
      dashboard that consolidates incoming patient-reported data using pre-programmed algorithms to
      identify increases in disease activity, and 2) the population manager, a trained individual
      who monitors the web-based dashboard and connects patients with their healthcare providers
      (HCPs). The investigators central hypothesis is that the combined smart phone app +
      population management system will improve patient satisfaction and management of RA disease
      activity.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived Efficacy in Patient-Physician Interactions Questionnaire (PEPPI)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Activity Scale-II (PAS-II)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flare Assessment in Rheumatoid Arthritis (FLARE) questionnaire</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Arthritis</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Mobile Application + Population Manager</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm of the study will contain half the study population after randomization. The participants in this arm will receive the mobile application with daily questions after the first visit. A population manager will review patient-reported symptoms via a web-base dashboard and contact the subject based on pre-specified guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Mobile Application</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm of the study will contain half the study population after randomization. The participants in this arm will not receive the mobile application after the first visit. Although participants will be provided with the contact information of a study staff member, there will be no active contact with the subject unless he/she initiates.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mobile Application</intervention_name>
    <description>A mobile health application that asks daily questions about participants' pain, function, and disease activity.</description>
    <arm_group_label>Mobile Application + Population Manager</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Population Management System</intervention_name>
    <description>Study staff will act as care managers behind a web-based dashboard to monitor participants' responses to the daily questions on the mobile application and connect them with their HCPs.</description>
    <arm_group_label>Mobile Application + Population Manager</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA by a board-certified rheumatologist

          -  Taking a DMARD (sulfasalazine, methotrexate, leflunomide, azathioprine, certolizumab,
             cyclosporine, adalimumab, etanercept, infliximab, golimumab, abatacept, tocilizumab,
             anakinra, tofacitinib, rituximab, hydroxychloroquine)

          -  Own a smart phone with either an Android or iPhone operating system

          -  Be English-speaking

        Exclusion Criteria:

          -  Patients who do not plan on receiving follow-up care at the Brigham and Women's
             Hospital Arthritis Center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Daniel H. Solomon, M.D.,MPH</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Mobile Health</keyword>
  <keyword>Pain</keyword>
  <keyword>Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

